

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



国药集团  
SINOPHARM

# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)*  
**(Stock Code: 01099)**

## ANNOUNCEMENT ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISORS

The board (the “**Board**”) of directors (the “**Directors**”) of Sinopharm Group Co. Ltd. (the “**Company**”) hereby announces that at the meeting of the employee representatives of the Company held on 14 September 2023, Mr. Liu Hongbing and Ms. Lu Haiqing were elected as employee representative supervisors of the sixth session of the supervisory committee with effect from 15 September 2023. In accordance with the articles of association of the Company, the employee representative supervisor shall be elected democratically by the employees of the Company and is not subject to the shareholders’ approval.

Biographical details of employee representative supervisors of the sixth session of the supervisory committee are as follows:

**Mr. Liu Hongbing**, aged 52. Mr. Liu served in the army force from 1987 to 2019, and engaged in propaganda work and theory and policy study. From January 2020 to March 2021, Mr. Liu acted as the head of the board office, the head of the publicity department of the Party Committee and the head of press office, and concurrently served as the deputy head of policy study office of China National Pharmaceutical Group Co., Ltd.. Mr. Liu has served as the employee representative supervisor of the Company since 17 June 2022 and is currently a member of the Party Committee and the secretary of discipline inspection commission of the Company.

**Ms. Lu Haiqing**, aged 49. Ms. Lu obtained a master’s degree in accounting from The Chinese University of Hong Kong in December 2012. Ms. Lu is a non-executive member of the Chinese Institute of Certified Public Accountants (CPA) and a non-executive member of the International Certified Internal Auditor (CIA) Association. Ms. Lu has approximately 29 years of working experience, among which experience obtained from February 2000 to June 2006 were all audit experience. She had served successively as the project manager of the audit department of Guangxi GuiXinCheng Certified Public Accountants Co., Ltd. (廣西桂鑫誠會計事務所), the project manager of the audit department of Shanghai Huadong Certified Public Accountants Co., Ltd., Guangxi Branch (上海華東

*\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

會計師事務所有限公司廣西分所), the project manager of the investment department of Shanghai Kangrun Investment Co., Ltd. (上海康潤投資有限公司), and the audit manager of the audit department of Bosideng Corporation Limited (波司登股份有限公司). Ms. Lu successively served as the audit manager and the deputy head of the audit department of the Company from July 2006 to March 2022. She has served as the deputy general manager of the audit center of the Company since April 2022 and an employee representative supervisor of the Company since September 2020. Ms. Lu currently also takes up senior management positions in a number of subsidiaries of the Company.

The Company will enter into a service contract with Mr. Liu Hongbing and Ms. Lu Haiqing, respectively. The term of office of them as the employee representative supervisors of the sixth session of the supervisory committee will be consistent with the term of office of the sixth session of the supervisory committee, being three years commencing from the date of approval of the proposed re-election of supervisors by the shareholders at the extraordinary general meeting to be held on 15 September 2023. Pursuant to the articles of association, they will be subject to retirement by rotation and re-election upon the expiry of his/her term of office as a supervisor. At present, according to the Company's 2023 remuneration standard, Mr. Liu Hongbing and Ms. Lu Haiqing will not receive any remuneration from the Company in their capacities as employee representative supervisors.

Save as disclosed above and as at the date of this announcement, the above employee representative supervisors of the sixth session of the supervisory committee do not have any relationships with any Directors, senior management, substantial or controlling shareholder(s) of the Company, or have any interest in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, the above employee representative supervisors of the sixth session of the supervisory committee did not hold any other positions in the Company or any of its subsidiaries, or any directorships in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matter that needs to be brought to the attention of the shareholders or any information in relation to the appointment of the above employee representative supervisors of the sixth session of the supervisory committee that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Yu Qingming**  
Chairman

Shanghai, the PRC  
14 September 2023

*As at the date of this announcement, the executive Directors are Mr. Yu Qingming and Mr. Liu Yong; the non-executive Directors are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.*